Biology and Pathology of Ovarian Cancer

Early Diagnosis and Treatment of Cancer Series: Ovarian Cancer

Volumn , Issue , 2010, Pages 17-32

  Jinawath, Natini ^a,b   Shih, Le Ming ^c,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861083381     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4685-1.50007-X     Document Type: Chapter

References (60)

1. Cho K, Shih IM Ovarian cancer. Ann Rev Pathol 2009, 4:287-313.
2. Scully RE International Histological Classification of Tumors: Histological Typing of Ovarian Tumors 1999, 3-44. World Health Organization, Geneva.
3. Tavassoli FA, Deville P Tumours of the Breast and Female Genital Organs: World Health Organization Classification of Tumours 2003, 117-145. IARC Press, Lyon.
4. Singer G, Kurman RJ, Chang H-W, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002, 160:1223-1228.
5. Ortiz BH, Ailawadi M, Colitti C, et al. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 2001, 61:7264-7267.
6. Bell DA, Scully RE Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994, 73:1859-1864.
7. Caduff RF, Svoboda-Newman SM, Ferguson AW, et al. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 1999, 23:323-328.
8. Dubeau L Ovarian cancer. The Metabolic and Molecular Bases of Inherited Disease 2001, 1091-1096. McGraw-Hill, Toronto. C.R. Scriver, A.L. Beaudet, W.S. Sly (Eds.).
9. Burks RT, Sherman ME, Kurman RJ Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996, 20:1319-1330.
10. Riopel MA, Ronnett BM, Kurman RJ Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 1999, 23:617-635.
11. Seidman JD, Kurman RJ Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996, 20:1331-1345.
12. Sehdev AES, Sehdev PS, Kurman RJ Noninvasive and invasive micropapillary serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol 2003, 27:725-736.
13. Okuda T, Otsuka J, Sekizawa A, et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol 2003, 88:318-325.
14. Modesitt SC, Tortolero-Luna G, Robinson JB, et al. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 2002, 100:788-795.
15. Horiuchi A, Itoh K, Shimizu M, et al. Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol 2003, 88:309-317.
16. Masuda A, Takeda A, Fukami H, et al. Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary. Carcinomatous cells are changeable to sarcomatous cells. Cancer 1987, 60:1697-2703.
17. Moritani S, Moriya T, Kushima R, et al. Ovarian carcinoma recurring as carcinosarcoma. Pathol Int 2001, 51:380-384.
18. Dehari R, Kurman RJ, Logani S, et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma-a morphologic and molecular genetic analysis. Am J Surg Pathol 2007, 31:1007-1012.
19. Peyssonnaux C, Eychene A The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001, 93:53-62.
20. Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95:484-486.
21. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
22. Rajagopalan H, Bardelli A, Lengauer C, et al. RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
23. Cheng EJ, Kurman RJ, Wang M, et al. Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 2004, 84:778-784.
24. Chan W-Y, Cheung K-K, Schorge JO, et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000, 156:409-417.
25. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993, 85:1513-1519.
26. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993, 90:4961-4965.
27. Berchuck A, Carney M Human ovarian cancer of the surface epithelium. Biochem Pharmacol 1997, 54:541-544.
28. Wen WH, Reles A, Runnebaum IB, et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999, 18:29-41.
29. Shelling AN, Cooke I, Ganesan TS The genetic analysis of ovarian cancer. Br J Cancer 1995, 72:521-527.
30. Pothuri B, Leitao M, Barakat R, et al. Genetic analysis of ovarian carcinoma histogenesis. Society of Gynecologic Oncologists 32nd Annual Meeting. Gynecol Oncol (Abstract) 2001, 80.
31. Gallardo A, Matias-Guiu X, Lagarda H, et al. Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases. Int J Gynecol Pathol 2002, 21:268-272.
32. Kounelis S, Jones MW, Papadaki H, et al. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998, 29:82-87.
33. Abeln EC, Smit VT, Wessels JW, et al. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol 1997, 183:424-431.
34. Sreenan JJ, Hart WR Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995, 19:666-674.
35. Singer G, Rebmann V, Chen YC, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003, 9:4460-4464.
36. Urosevic M, Kurrer MO, Kamarashev J, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001, 159:817-824.
37. Urosevic M, Willers J, Mueller B, et al. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002, 99:609-617.
38. Chen YC, Pohl G, Wang TL, et al. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 2005, 65:331-337.
39. Shih YC, Kerr J, Hurst TG, et al. No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms. Gynecol Oncol 1998, 69:210-213.
40. Allen HJ, DiCioccio RA, Hohmann P, et al. Microsatellite instability in ovarian and other pelvic carcinomas. Cancer Genet Cytogenet 2000, 117:163-166.
41. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993, 53:1489-1492.
42. Ichikawa Y, Nishida M, Suzuki H Mutation of KRAS protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994, 54:33-35.
43. Enomoto T, Weghorst CM, Inoue M, et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991, 139:777-785.
44. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gyncol Oncol 2003, 90:378-381.
45. Wu R, Zhai Y, Fearon ER, et al. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001, 61:8247-8255.
46. Moreno-Bueno G, Gamallo C, Perez-Gallego L, et al. Beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001, 10:116-122.
47. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998, 58:2095-2097.
48. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000, 60:7052-7056.
49. Saito M, Okamoto A, Kohno T, et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 2000, 85:160-165.
50. Thomas EJ, Campbell IG Molecular genetic defects in endometriosis. Gynecol Obstet Invest 2000, 50:44-50.
51. Obata K, Hoshiai H Common genetic changes between endometriosis and ovarian cancer. Gynecol Obstet Invest 2000, 50:39-43.
52. Bischoff FZ, Simpson JL Heritability and molecular genetic studies of endometriosis. Hum Reprod Update 2000, 6:37-44.
53. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005, 11:63-70.
54. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007, 11:321-333.
55. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003, 163:2503-2512.
56. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000, 60:6281-6287.
57. Francis-Thickpenny KM, Richardson DM, van Ee CC, et al. Analysis of the TGF-beta functional pathway in epithelial ovarian carcinoma. Br J Cancer 2001, 85:687-691.
58. Fujita M, Enomoto T, Yoshino K, et al. Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer 1995, 64:361-366.
59. Gras E, Catasus L, Arguelles R, et al. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 2001, 92:2829-2836.
60. Druker BJ Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002, 1:31-36.